Nexavar
Developed to address carcinoma growth to alleviate tumour progression.
Strengths: 200mg
Where to Check Availability
Medicine details
- Therapeutic class
Kinase inhibitor
- Pharmacological class
Antineoplastic agent
- Contraindications
hypersensitivity to sorafenib; pregnancy
- Minor side effects
diarrhoea; fatigue; alopecia; rash; hand-foot syndrome
- Moderate side effects
hypertension; weight loss; anorexia
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Patient summary
Developed to address carcinoma growth to alleviate tumour progression.
- Prescription status
POM
- Manufacturer
Bayer
- Onset Time
Variable
- Duration
Ongoing
- Storage instructions
Store below 25°C.
- Drug interactions
Warfarin; Docetaxel
- Age restrictions
Not for children.
- Pregnancy and breastfeeding
Pregnancy: Use is contraindicated. Breastfeeding: Discontinue during treatment.
Precautions and warnings
monitor skin reactions; check blood pressure regularly; discontinue if cardiac ischaemia occurs
Serious side effects
cardiac ischaemia — requires immediate medical attention; haemorrhage — requires immediate medical attention; gastrointestinal perforation — requires immediate medical attention
Mechanism of action
Sorafenib is a multikinase inhibitor that suppresses tumour cell proliferation and angiogenesis by inhibiting intracellular and cell surface kinases.
Nexavar
Developed to address carcinoma growth to alleviate tumour progression.
Editorial Notes
- Active ingredient(s): Sorafenib
- Listed indication(s): Hepatocellular Carcinoma, Renal Cell Carcinoma, Differentiated Thyroid Carcinoma
Available option
- 30 tablets - 200 mg1474-200-mg-17754